NKF advises Boston Scientific as Swiss Counsel on the acquisition of Symetis
Niederer Kraft Frey advised Boston Scientific Corporation, USA as Swiss counsel on the acquisition of Symetis SA for USD 435 million. Headquartered in Ecublens, Switzerland, Symetis is a leading European developer of innovative, minimally invasive heart valve replacement devices. The transaction is subject to antitrust approval, and closing is anticipated for the second half of 2017.
The NKF team was led by András Gurovits (partner, Technology, Corporate/M&A) and Patrik Peyer (partner, Corporate/M&A) and further consisted of Daniela Schmucki (partner, Tax), Valerie Meyer Bahar (partner, Employment), Evelyn Schilter (senior associate, Corporate/M&A), Roman Sturzenegger (senior associate, Corporate/M&A), Mirjam Vögeli (senior associate, Corporate/M&A), Livia Keller (associate, Employment), Teuta Imeraj (associate, Tax), Daniel Juri (junior associate, Corporate/M&A) and Rune Müller (junior associate, Corporate/M&A).
NKF acted alongside Latham & Watkins, who acted as international counsel to Boston Scientific Corporation.